Loading...
12/16 00:48
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reflects strong financial performance with revenue growth, improved margins, and positive adjusted EBITDA. Despite challenges in the biotech sector, the company is exploring new revenue streams through data licensing and maintaining operational efficiency. The Q&A section highlights management's proactive approach in navigating market conditions and exploring partnerships, although some details were withheld. Overall, the strong financial results, optimistic guidance, and potential for recurring revenue from licensing support a positive stock price outlook.
Total Revenue $17 million, an increase of 42% year-over-year from $12 million in the prior year, driven by the successful closure of the inaugural data deal and growth in core services.
Research Service Revenue $12.5 million, up from $12 million year-over-year, reflecting stable demand in core services.
Data Revenue Contribution $4.5 million, indicating early traction of the new platform.
Income from Operations $4.5 million, compared to a loss of $2.6 million in the prior year, attributed to improved operational efficiency and revenue growth.
Adjusted EBITDA $5.2 million, compared to an adjusted loss of $1.7 million in the prior year, reflecting strong revenue growth and cost management.
Total Cost of Sales $6.6 million, a decrease of 16% from $7.8 million in the prior year, primarily due to reduced salary expenses and lab costs.
Gross Margin 61%, improved due to high margin data revenue.
Research Service Margins 48%, up from 35% year-over-year, indicating improved efficiency in service delivery.
R&D Expense $1.7 million, a decrease of 21% from the prior year, reflecting optimized spending.
Total Revenue Year-to-Date $45 million, an increase of 22% from $36 million in the same period last year.
Total Cost of Sales Year-to-Date $21 million, a decrease of 4% from $21.9 million in the prior year.
Total Gross Margin Year-to-Date 53%, improved from 40% year-over-year, driven by high margin data revenue and operational efficiencies.
Adjusted EBITDA Year-to-Date $8.3 million, compared to an adjusted loss of $4.8 million in the prior year.
Cash Position $3.2 million, with no debt, reflecting a solid balance sheet.
Cash Generated by Operating Activities $900,000 for the quarter, indicating improved operational results.
Cash Used in Investment Activities Approximately $500,000, contributing to a net increase in cash of $400,000 for the quarter.
Record Revenue: Champions Oncology reported record revenue of $17 million for Q3 2025.
Data Revenue Contribution: Data revenue contribution was $4.5 million, indicating early traction of the new platform.
Core Services Business: The core services business is driven by the industry-leading PDX bank and its multiomic data.
Cost Management: Operational efficiencies have led to improved cost management and profitability.
Gross Margin: Gross margin for the quarter was 61%, lifted by high-margin data revenue.
R&D Expense Reduction: R&D expense declined by 21% to $1.7 million as part of cost optimization.
Data Deal: Champions Oncology successfully closed its inaugural data deal, licensing its deep multiomic data set.
Expansion of Data Set: The company is actively exploring ways to extract greater value from its data and expand its collection of unique tumor models.
Long-term Growth Strategy: The company aims to build the world's most comprehensive biological data set from clinically relevant tumor populations.
Market Environment: The environment remains tight, leading to potential performance volatility despite a mild improvement in the sector.
Funding Challenges: The company is facing a challenging funding environment, which may impact their capital raising efforts for their drug development subsidiary, Corellia.
Revenue Projections: It remains premature to forecast the number of deals, their average size, or the frequency with which they will occur, creating uncertainty in data revenue contributions.
Operational Volatility: Research service margins are expected to fluctuate over the next two quarters due to anticipated balance related in revenue and cost of sales.
Economic Factors: The company is cautiously optimistic about a rebound in the biotech sector, but economic factors may still pose risks to growth.
Record Revenue: Q3 marked a transformative quarter for Champions Oncology, underscored by our record revenue of $17 million.
Data Deal: Successful closure of our inaugural data deal, licensing our existing deep multiomic data set.
PDX Bank Expansion: Consistent expansion of our collection of unique tumor models and enhancing their characterization.
AI Integration: Recognizing the rise of AI to extract deeper insights from biological data, increasing demand for our data set.
Corellia Development: Optimistic about targets and compounds developed using proprietary data, actively engaged in capital raising discussions.
Revenue Growth Guidance: Reaffirmed full year revenue growth guidance of 10% to 15%.
Long-term Margin Expansion: Anticipate long-term margin expansion exceeding 15% as long-term revenue growth continues.
Cash Position Outlook: Expect cash position to increase in the coming quarters as operational results improve.
Performance Volatility: Despite mild improvement in the sector, the environment remains tight, leading to potential performance volatility.
Shareholder Return Plan: We have reaffirmed our full year revenue growth guidance of 10% to 15% and continue to focus on expanding our data business, enhancing profitability and driving shareholder value.
Cash Position: We ended the quarter with $3.2 million of cash on the balance sheet and no debt.
Cash Generated: For the quarter, cash generated by operating activities was $900,000.
Cash Used in Investment Activities: Cash used in investment activities was approximately $500,000.
Quarterly Cash Increase: The net $400,000 quarterly increase in cash was primarily from an improvement in operational results.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
